Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rozanolixizumab May Offer New Treatment Paradigm for ITP

Publish date:: July 3, 2019

Key clinical point: Rozanolixizumab, a subcutaneous antibody targeting the human neonatal Fc receptor, provides clinically meaningful improvements in platelet count for patients with primary immune thrombocytopenia.

Major finding: Out of 12 patients, 8 in the highest dose group achieved platelet counts of 5 x 10⁹/L or higher.

Study details: A phase 2, open-label study involving 54 patients with immune thrombocytopenia.

Disclosures: The investigators reported financial relationships with Celgene, Roche, GlaxoSmithKline, Amgen, AbbVie, and other companies.

Citation:

Robak T et al. EHA Congress, Abstract S850.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,